MedTrace Logo

Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

NCT00307723 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2009-08-10

No results posted yet for this study

Summary

The purpose of this study is determine the safety of bevacizumab, oxaliplatin, 5-FU, and gemcitabine in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating patients with locally advanced pancreatic cancer (Phase II portion).

Conditions

Interventions

DRUG

bevacizumab

Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.

DRUG

5-Fluorouracil

Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.

DRUG

Oxaliplatin

Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.

DRUG

gemcitabine

Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.

PROCEDURE

External Beam Radiation Therapy

Monday through Friday ending on day 38 of cycle 1

Sponsors & Collaborators

Principal Investigators

  • Lawrence S. Blaszkowsky, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-08-31
Completion
2009-07-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307723 on ClinicalTrials.gov